Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Phase 3 Cancer Trials

Pittsburgh, Pennsylvania

Phase 3 cancer trials in Pittsburgh, PA

63 Phase 3 cancer studies are recruiting participants at sites in Pittsburgh as of November 18, 2026, according to ClinicalTrials.gov. Phase 3 Cancer Trials can help you understand your options and connect with a study team.

Call (888) 306-7888
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Pittsburgh at a glance

Breast cancer studies recruiting in Pittsburgh

Basic details from each study's public record (the 30 most recently updated of 63). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Allegheny General Hospital · UPMC Hillman Cancer Center · UPMC-Magee Womens Hospital
    Registry record
    NCT06058377 · updated
  2. A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)

    • Phase 3
    • Ages 18 and older
    • Female participants
    Sponsor
    Genentech, Inc.
    Study site
    Magee Womens Hospital
    Registry record
    NCT07541079 · updated
  3. Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Gilead Sciences
    Study site
    UPMC Magee-Womens Hospital
    Registry record
    NCT05633654 · updated
  4. Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

    • Phase 3
    • Ages 18 to 60
    • Female participants
    Sponsor
    NRG Oncology
    Study sites
    Allegheny General Hospital · UPMC Hillman Cancer Center · UPMC-Magee Womens Hospital
    Registry record
    NCT05879926 · updated
  5. E-Mindfulness Approaches for Living After Breast Cancer

    • Phase 3
    • Ages 18 to 50
    • All sexes
    Sponsor
    NRG Oncology
    Study sites
    UPMC Hillman Cancer Center · UPMC-Magee Womens Hospital · UPMC-Saint Margaret
    Registry record
    NCT06748222 · updated
  6. A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    UPMC Hillman Cancer Center - Magee-Women?s Hospital
    Registry record
    NCT06790693 · updated
  7. A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    University of Pittsburgh Medical Center Magee-Womens Hospital ( Site 0058)
    Registry record
    NCT07060807 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Pittsburgh, PA on ClinicalTrials.gov.

Lung cancer studies recruiting in Pittsburgh

  1. Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    UPMC Hillman Cancer Center
    Registry record
    NCT06498635 · updated
  2. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Summit Therapeutics
    Registry record
    NCT06767514 · updated
  3. JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    University of Texas Southwestern Medical Center
    Study site
    Allegheny
    Registry record
    NCT02468024 · updated
  4. LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    NovoCure GmbH
    Study site
    AHN Cancer Center
    Registry record
    NCT06216301 · updated
  5. Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    UPMC Hillman Cancer Center · UPMC-Mercy Hospital · UPMC-Passavant Hospital
    Registry record
    NCT04267848 · updated
  6. Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    West Penn Allegheny Health
    Registry record
    NCT07100080 · updated
  7. DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Boehringer Ingelheim
    Study site
    AHN Cancer Institute - Allegheny General
    Registry record
    NCT07472517 · updated
  8. A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    Allegheny Cancer Center
    Registry record
    NCT06793215 · updated
  9. A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    UPMC Hillman Cancer Center
    Registry record
    NCT06119581 · updated
  10. A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Bayer
    Study site
    Allegheny General Hospital
    Registry record
    NCT06452277 · updated
  11. Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    AHN Allegheny General Hospital
    Registry record
    NCT06890598 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Pittsburgh, PA on ClinicalTrials.gov.

Prostate cancer studies recruiting in Pittsburgh

  1. Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Study sites
    UPMC Hillman Cancer Center · UPMC-Magee Womens Hospital · UPMC-Passavant Hospital
    Registry record
    NCT04423211 · updated
  2. Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    Allegheny General Hospital · West Penn Hospital
    Registry record
    NCT06931340 · updated
  3. A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    Janssen Research & Development, LLC
    Study site
    UPMC Cancer Centers
    Registry record
    NCT07164443 · updated
  4. A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study site
    University Of Pittsburgh Medical Center UPMC Hillman Cancer Center
    Registry record
    NCT07225946 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Pittsburgh, PA on ClinicalTrials.gov.

Melanoma studies recruiting in Pittsburgh

  1. Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma

    • Phase 3
    • Ages 75 and older
    • All sexes
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Study site
    UPMC Hillman Cancer Center
    Registry record
    NCT07068074 · updated
  2. A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Regeneron Pharmaceuticals
    Study site
    University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center
    Registry record
    NCT06246916 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Pittsburgh, PA on ClinicalTrials.gov.

Lymphoma studies recruiting in Pittsburgh

  1. SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Nuvation Bio Inc.
    Study site
    UPMC Hillman Cancer Center
    Registry record
    NCT05303519 · updated
  2. ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Newave Pharmaceutical Inc
    Study site
    UPMC Hillman Cancer Center
    Registry record
    NCT07342478 · updated
  3. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Children's Hospital of Pittsburgh of UPMC
    Registry record
    NCT05675410 · updated
  4. A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    BeOne Medicines
    Study site
    West Penn Hospital
    Registry record
    NCT06846671 · updated
  5. Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

    • Phase 3
    • Ages 12 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    Allegheny General Hospital · UPMC Hillman Cancer Center · UPMC-Shadyside Hospital
    Registry record
    NCT07215910 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Pittsburgh, PA on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in Pittsburgh

  1. A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Incyte Corporation
    Study site
    Investigative Site US056
    Registry record
    NCT07522073 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Pittsburgh, PA on ClinicalTrials.gov.

Ask about studies near Pittsburgh

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Pennsylvania

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 3, including combined Phase 2/3, as each study is coded in the registry.

Phase 3 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 306-7888

or send a short form

How should we reach you?

Call